|
|
Summary ToggleZafgen Secures $45 Million in Series E Financing
- Proceeds to Advance Development of Obesity Therapeutic Beloranib -
|
Summary ToggleZafgen Secures $45 Million in Series E Financing
|
|
|
Summary ToggleZafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
Final Study Results Demonstrate Treatment with Beloranib Led to Significant Weight Loss and Improvements in Multiple Cardiometabolic Risk Factors in 147 Obese Subjects
|
Summary ToggleZafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
|
|
|
Summary ToggleZafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions®
Interim Results Show Treatment with Beloranib Resulted in Clinically Meaningful Body Weight Loss and Improvements in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects
|
Summary ToggleZafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions®
|
|
|
Summary ToggleZafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer
Ms. Allen Brings Significant Public Company Experience as Zafgen Continues to Evaluate its Strategic Options
|
Summary ToggleZafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer
|
|
|
Summary ToggleZafgen Secures $21 Million in Series D Financing
Alta Partners Joins Investor Syndicate to Lead New Funding<br /><br />Proceeds to Advance Development of Obesity Therapeutic Beloranib
|
Summary ToggleZafgen Secures $21 Million in Series D Financing
|
|
|
Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
|
Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
|
|
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society
Findings Show Treatment with Beloranib Resulted in Rapid Weight Loss, Corresponding Reductions in Multiple Cardiovascular Risk Factors in Severely Obese Subjects
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society
|
|
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
Results Show Treatment with Beloranib Resulted in Weight Loss and Corresponding Reductions in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
|
|
|
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
|
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
|
|
|
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
|
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
|